ACP5 and Spondyloenchondrodysplasia with immune dysregulation: Janus kinase inhibitor therapy for the treatment of spondyloenchondrodysplasia with immune dysregulation due to novel &lt;i&gt;ACP5&lt;/i&gt; variants: a multicenter study.